Table 3 Funding sources for interventional studies
| Year | Supported by pharma companies | Supported within EC sarcomas’ projects | Supported by ISG |
|---|---|---|---|
| 2010 | 2/4 (50%) | 0 (0%) | 2 (50%) |
| 2011 | 4/7 (57%) | 1 (14%) | 2 (29%) |
| 2012 | 3/7 (43%) | 1 (14%) | 3 (43%) |
| 2013 | 3/7 (43%) | 1 (14%) | 3 (43%) |
| 2014 | 6/12 (50%) | 3 (25%) | 3 (25%) |
| 2015 | 6/13 (46%) | 4 (31%) | 3 (23%) |
| 2016 | 9/17 (52%) | 4 (24%) | 4 (24%) |